Doximity DOCS NYSE · Healthcare · United States
$29.62 -3.42% -$1.05
Summary
77 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 23% a year over the last 3 years.
- Out of every 100 USD of revenue, 21 USD is left as net profit.
- It holds more cash than debt: $218.6M against $9.15M.
- It bought back its own shares for $431.7M in the last fiscal year, 8.2% of its market value.
What to watch
- You pay 37.8 USD for 1 USD of yearly profit, a lot for its sector.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBy our assumptions the price matches the value of the business: the two differ by less than 10 %.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 37.8 USD for 1 USD of yearly profit. Over the last five years it was 47.8 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 26% a year over 5 years. Over the last 3 years it grew by 15% a year. For the next fiscal year analysts expect revenue to grow by 5.5%. Earnings per share grew by 23% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 13 USD
- Research and development 23 USD
- Sales and administration 37 USD
- Taxes and other 5.2 USD
- Net profit 21 USD
Net profit, industry median (Medical - Healthcare Information Services) 5.7 USD
Out of every 100 USD of revenue, 21 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 9
- Hold 13
- Sell 2
Today's price within the analysts' price targets
The average target of $31.75 is 7.2% above today's price. 38% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2026By product
- Subscription 94%
- Service, Other 5.7%
By region
The company reports no revenue by region.
Subscription brings in 94% of revenue.
Segments in detail